What Should a Corporation Know about Buy-Sell Agreements?

Without a buy-sell agreement, the death or departure of a shareholder can trigger legal and operational problems. When a shareholder dies and leaves equity to an heir with no business experience, the remaining owners may face disputes over valuation, forced co-ownership with a stranger, or demands for an inflated buyout price.

A buy-sell agreement locks in a valuation methodology, specifies who has the right or obligation to purchase the departing owner's stake, and establishes a timeline and payment structure. This clarity protects the corporation's continuity and prevents the remaining owners from being forced to negotiate under duress. For the departing owner or their estate, the agreement offers certainty about equity value and payment timing.

Buy-sell agreements also address tax efficiency. By documenting the purchase price in advance, the agreement can establish a valuation for estate tax purposes, potentially reducing the taxable estate of the deceased shareholder. Many corporations pair buy-sell agreements with life insurance or disability insurance, ensuring the purchasing party has the liquidity to close the transaction without depleting working capital.

Buy-sell agreements typically activate upon death, disability, retirement, voluntary resignation, or termination for cause. Each trigger may carry different purchase terms, pricing formulas, and payment schedules.

A cross-purchase agreement allows the remaining shareholders to buy the departing shareholder's stock directly. Each shareholder often owns life insurance on the other shareholders, and when one dies, the insurance proceeds fund the purchase. A redemption agreement obligates the corporation itself to repurchase the departing shareholder's stock. The corporation funds the redemption through accumulated cash, a line of credit, or insurance proceeds it holds on the shareholder's life.

Valuation formulas vary widely. Some agreements fix a price in advance and update it annually. Others use a formula tied to earnings, book value, or a multiple of revenue. Still others require an appraisal by an independent third party if the parties cannot agree. The choice of formula has enormous practical impact: an undervalued formula may discourage the departing owner from accepting the deal, and an overvalued formula can strain the purchasing party's liquidity.

Funding is the linchpin of enforceability. If a buy-sell agreement obligates the corporation or remaining shareholders to purchase equity but provides no mechanism to pay, the agreement becomes a source of conflict rather than clarity.

Life insurance is the most common funding vehicle. The corporation or cross-purchasing shareholders own policies insuring the life of each shareholder. Upon death, the insurance proceeds are paid to the purchaser, who then uses those funds to complete the stock purchase. This approach ensures liquidity at the moment the obligation arises. Some corporations also establish a sinking fund, setting aside cash reserves annually to accumulate the capital needed for a future buyout.

A critical procedural consideration is that the corporation must ensure insurance policies are properly owned, that beneficiary designations align with the buy-sell agreement's intent, and that the agreement itself references the insurance and specifies how proceeds will be applied. If a policy lapses due to missed premiums, or if a beneficiary designation conflicts with the agreement, a court may have to resolve disputes over whether the deceased owner's estate is entitled to the insurance proceeds or whether the remaining owners can claim them to fund the purchase. In New York practice, delayed or incomplete documentation of the insurance arrangement can create a procedural barrier to summary judgment on enforceability.

Corporations must anticipate that buy-sell agreements can face legal challenges from estates, departing owners, or remaining shareholders who claim the agreement is unenforceable, was procured by fraud, or does not reflect the parties' true intent.

A common defense is that the agreement was not properly executed or acknowledged. If the agreement was drafted informally, signed without counsel, or lacks evidence of mutual assent, a court may find it too vague or lacking in essential terms. Another defense is that the valuation formula is unreasonable or has become obsolete due to material changes in the business.

The corporation should also consider whether the agreement contains a non-compete or non-solicitation provision. If a departing shareholder is also an officer or employee, the buy-sell agreement may restrict that person from competing with the corporation or soliciting its customers after departure. Enforceability of these ancillary provisions depends on whether they are reasonable in scope, geography, and duration under state law. Consulting agreements that govern post-departure services or non-compete obligations should be coordinated with the buy-sell agreement to avoid conflicts.

A strategic procedural step is to ensure the buy-sell agreement is properly recorded or filed, where applicable, and that all shareholders receive a fully executed copy. The corporation should also maintain contemporaneous documentation of how the valuation was determined each year and any amendments or waivers the parties agreed to.

Before executing a buy-sell agreement, the corporation should conduct a checklist of structural and operational items to reduce the risk of disputes and ensure the agreement can be enforced as written.

The corporation should ensure that the buy-sell agreement is coordinated with other governance documents, such as the shareholder agreement, operating agreement, and bylaws. If these documents conflict, a court may find the buy-sell agreement ambiguous and refuse to enforce it. Each shareholder should receive independent legal counsel before signing, or at minimum, the corporation should obtain a written acknowledgment that they had the opportunity to consult with counsel and understood the terms.

For corporations with multiple shareholders, buy-sell agreements should be revisited every three to five years to confirm that the valuation formula still reflects market conditions and that insurance coverage remains adequate and in force. A lapsed insurance policy or an obsolete valuation formula can render the agreement unworkable in a crisis.

The most immediate step is to audit the corporation's existing buy-sell agreement against the checklist above. Verify that insurance policies are current, beneficiary designations are aligned with the agreement, and the valuation methodology has been applied consistently. If the agreement has not been reviewed in more than five years, or if the business has undergone significant changes, schedule a meeting with counsel to assess whether amendments are necessary.

If the corporation does not yet have a buy-sell agreement, now is the time to draft one. Delaying this step increases the risk that a shareholder will die or become disabled without a clear succession plan. The cost of drafting a buy-sell agreement upfront is far lower than the cost of resolving disputes after the fact.

Finally, ensure that all shareholders understand the agreement's terms and have received copies. Consider scheduling an annual meeting confirming that the agreement remains in effect and that insurance premiums are being paid. This ongoing communication reduces the risk of disputes and ensures that when a trigger event occurs, all parties are prepared to execute the transaction smoothly.